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Background: Women have elevated rates of thyroid disease compared to men. Environmental toxicants have been
implicated as contributors to this dimorphism, including polybrominated diphenyl ethers (PBDEs), flame retardant
chemicals that disrupt thyroid hormone action. PBDEs have also been implicated in the disruption of estrogenic
activity, and estrogen levels regulate thyroid hormones. Post-menopausal women may therefore be particularly
vulnerable to PBDE induced thyroid effects, given low estrogen reserves. The objective of this study was to test for
an association between serum PBDE concentrations and thyroid disease in women from the United States (U.S.),
stratified by menopause status.
Methods: Serum PBDE concentrations (BDEs 47, 99, 100 and 153) from the National Health and Examination Survey
(NHANES) and reports on thyroid problems were available in the NHANES 2003–2004 cycle. Odds ratios (ORs) were
calculated using multivariate logistic regression models accounting for population-weighted survey techniques and
controlling for age, body mass index (BMI), education, smoking, alcohol consumption and thyroid medication.
Menopause status was obtained by self-reported absence of menstruation in the previous 12 months and declared
menopause.
Results: Women in the highest quartile of serum concentrations for BDEs 47, 99, and 100 had increased odds of
currently having thyroid disease (ORs: 1.5, 1.8, 1.5, respectively) compared to the reference group (1st and 2nd
quartiles combined); stronger associations were observed when the analysis was restricted to postmenopausal
women (ORs: 2.2, 3.6, 2.0, respectively).
Conclusion: Exposure to BDEs 47, 99, and 100 is associated with thyroid disease in a national sample of U.S.
women, with greater effects observed post-menopause, suggesting that the disruption of thyroid signaling by
PBDEs may be enhanced by the altered estrogen levels during menopause.
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Fire safety standards promulgated in California in the late
1970’s have led to the proliferation of chemical flame re-
tardants (FRs) used in consumer products worldwide [1].
Brominated flame retardant compounds are used as addi-
tives in products at up to 20 % by weight of the product
[2]. Precisely because they are used as additives, rather
than covalently bound to a polymer matrix, these haloge-
nated FRs can and do migrate from their source products
into the indoor and outdoor environment [3]. In fact, the
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nated diphenyl ethers (PBDEs), has led to their near
ubiquitous presence in animals, abiotic matrices and
food, as well as in air, dust and surfaces of indoor envi-
ronments [4–17].
PBDEs share a similar structure to polychlorinated
biphenyls (PCBs), polybrominated biphenyls (PBBs), tetra-
bromobisphenol A (TBBPA), triclosan, and the halogenated-
phenyl ring of thyroid hormone thyroxine (T4), with the
potential for 209 different congeners based on the num-
ber and position of the bromine within the aromatic
rings. PBDEs were manufactured in three commercial
products—PentaBDE, OctaBDE, DecaBDE—each of
which is dominated by one or more congeners (BDEs 47s distributed under the terms of the Creative Commons Attribution 4.0
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bromodiphenyl ether), 100 (2,2′,4,4′,6-penta-bromodiphenyl
ether); BDE 183 (2,2′,3,4,4′,5′,6-hepta-bromodiphenly ether);
BDE 209 (deca-bromodiphenyl ether), respectively). The
use of PBDEs as flame retardants have been phased out or
banned in some countries, and updated California fire
safety standards no longer require PBDEs or other flame
retardant chemicals to be used in furniture [18]. However,
exposure is expected to continue for several decades
because of the reservoir of these chemicals that exist in
consumer products that have long durations of use (e.g.
couches), and the environmental stability of PBDEs. The
most recent data available from NHANES shows that a
reduction in PBDEs in serum was not yet observed on a
national level following the phase-out of several PBDEs in
2004 [19], although more current biomonitoring data
suggest that levels are decreasing [20, 21].
We have known for over 20 years that some PBDEs
are carcinogenic. A study by the National Toxicology
Program reported in 1986 found that DecaBDE causes
thyroid and liver tumors in rats and mice [22]. More
recently, a NTP study on PBDEs found that DE71, the
major commercial mixture of PentaBDE, is a two-species,
two-sex carcinogen [23]. Epidemiological evidence dem-
onstrates that PBDEs are also endocrine-disrupting com-
pounds that interfere with thyroid hormone action
[24], reproduction, and neurodevelopment [25–30]. Subtle
changes in circulating thyroid hormone concentrations
(e.g., free and total T3 (triiodothyronine), T4, TSH
(thyroid stimulating hormone)) are associated with many
adverse health effects. Thyroid hormones regulate the
growth and differentiation of the brain and are therefore
critical for neurodevelopment [31]; the developing fetus
relies on maternal thyroid hormone until week 11 of
gestation [32] before beginning to produce endogenous
hormones, and doesn’t produce sufficient hormone for its
own needs until approximately week 20 [33]. Further,
because the thyroid is a modulator for many of the body’s
organs, studies have linked thyroid conditions with other
diseases like kidney [34], liver [35], and heart [36].
Thyroid disorders disproportionately impact women
[37], and the rates of thyroid cancer are increasing glo-
bally, with women having higher rates of thyroid cancer
than men, and older women having higher rates than
younger women [38]. We know of only one study that
evaluated PBDE-associated health effects in a represen-
tative U.S. population sample (NHANES) and those
researchers found associations with diabetes and meta-
bolic syndrome [39], but did not evaluate thyroid disease
as an outcome. Further, we know of no research related to
the potential sensitivity of menopausal women to thyroid
disease based on PBDE concentration, despite the well-
described role of estrogen on thyroid function [40] and
the ability of PBDEs to exert estrogenic effects [41]. Theobjective of our research was to explore the relationship
between PBDE exposures in women and thyroid disease




At the time of publication, NHANES reported PBDE con-
centrations in serum for individuals (i.e., not pooled) for
only one NHANES cycle: 2003–2004. We analyzed the
data for the four PBDE congeners reported by NHANES
(BDEs 47, 99, 100 and 153), all primarily associated with
the PentaBDE commercial product; information on BDE
209, the primary congener of the DecaBDE commercial
product, has yet to be reported in any NHANES cycle.
Other researchers thoroughly describe the NHANES ana-
lytical methods for serum PBDE measurements and sum-
mary statistics for the population-weighted concentrations
[42]. We created exposure categories based on quartiles of
lipid-adjusted, sex-specific serum concentrations for each
congener as reported by Sjodin et al. [42]. In addition, we
generated a variable for total sum of lipid-adjusted PBDE
concentrations, which combined the concentrations from
the four congeners (ΣBDE).
Outcome variable—thyroid disease
Thyroid hormone measurements are available in NHANES
but did not overlap completely with the participants for
whom PBDE serum measurements were also available. The
NHANES questionnaire administered to all participants
in NHANES 2003–2004 included two questions related to
thyroid disease: MCQ160m “Has a doctor or other health
professional ever told (you/SP) that (you/s/he) . . . had a
thyroid problem?” and, MCQ170m “(Do you/Does SP)
still . . . have a thyroid problem?”. Responses included: yes,
no, don’t know or missing. For our analyses, if a subject
responded “don’t know” then the data were considered
missing. We used a combination of the thyroid questions
to develop an outcome variable ‘current thyroid problem’.
We defined having a current thyroid problem as an
affirmative answer to ever having a thyroid problem and
still have a thyroid problem. The sample size for partici-
pants with both PBDE measurements and thyroid disease
status available are as follows: BDE 47, n = 1396; BDE 99,
n = 1378; BDE 100, n = 1413; BDE 153, n = 1413.
Thyroid disease prevalence
To calculate the survey-weighted prevalence of thyroid
problems among the NHANES population, we generated
weighted proportions by gender and post-menopause for
questions MCQ160m (ever) and MCQ170m (current)
according to the NHANES descriptive statistical meth-
odology [43].
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We performed statistical analyses using STATA statis-
tical software package, version 13.0 (StatCorp, College
Station, TX). To estimate odds ratios and 95 % confi-
dence intervals for development of disease accounting
for the clustered sampling design in NHANES Control
and Prevention (CDC), we used multivariate logistic re-
gression modeling following procedures recommended
by the Centers for Disease Control and Prevention [44].
We performed logistic regression analyses in this study
using the STATA ‘svy’ commands to account for NHANES
strata and cluster variables, and represent population-
weighted results. To stratify the analysis to women-only,
we assigned men a near zero weight in accordance with
NHANES guidance. To stratify for women who were
postmenopausal, we created a variable based on women
who had not had one menstrual period in the last
12 months (RHQ031) and also indicated the reason for
not having a period was post-menopause/hysterectomy
(RHD042). Similar to the gender stratification, we
assigned near zero weights to all men and women who
were not postmenopausal.
We adjusted multivariate models for several potential
confounders, using a similar methodology from a recent
study examining thyroid effects in the NHANES study
[45]. Covariates included in the model, with groupings
in parentheses, were: race/ethnicity (Mexican American,
other Hispanic, non-Hispanic White, non-Hispanic
Black, other race (including multi-racial)); age (continuous
variable); body mass index (BMI) (less than 25, 25–30,
>30), education (less than high school, high school, more
than high school), smoking (ever/never smoked more than
100 cigarettes in lifetime); alcohol consumption (never
consume or at least one drink per week); and current
hormone use (taking birth control pills now, now using
Depo-Provera or injectables, taking estrogen only pills
now, taking progestin only pills now, taking estrogen/pro-
gestin now, using estrogen-only patches now, using estro-
gen/progestin patch now).
In the primary models, the first and second quartile
exposure groups (Q1 and Q2) were combined to increase
statistical power and match the approach necessitated for
BDE 99 (for BDE 99, the median serum concentration
reported by Sjodin et al. [44] was ‘non-detect’), similar to
the approach used by Melzer et al. [45].
Results
In the 2003–4 NHANES survey, the prevalence of
women reporting ever being told by a doctor that they
had a thyroid problem was five times higher than the
prevalence reported by men (16 % v. 3 %; p < 0.05). This
was similar to the finding for those reporting a current
thyroid problem (13 % v. 2 %; p < 0.05) (Table 1). In
comparisons of postmenopausal and premenopausalwomen, we found that the prevalence of ever having a
thyroid problem and the prevalence of currently having
a thyroid problem was twice as high for postmenopausal
women (ever: 24 % v. 12 %, p < 0.05; current: 18 % v.
10 %, p < 0.10).
In fully-adjusted, survey-weighted logistic regression
models we found that women in the highest quartile of
serum concentrations for BDE 47, 99, 100 and ΣBDE,
had a greater odds of currently having a thyroid prob-
lem, compared to women in the lower quartiles of serum
concentrations (Table 2); statistically significant associa-
tions were observed for BDE 47 (OR: 1.48; 95 % CI:
1.05–2.09), BDE 99 (OR: 1.78; 95 % CI: 1.16–2.75) and
ΣBDE (OR: 1.61; 95 % CI: 1.1–2.4), and marginally sig-
nificant for BDE 100 (OR: 1.50; 95 % CI: 0.97–2.31). The
point estimates of the odds ratios for the 3rd quartile
were less than unity, although only statistically significant
for the ΣBDE variable.
For all PBDE congeners except for BDE 153, the odds
ratios for women in the highest exposure category were
higher when the analysis was restricted to postmeno-
pausal women. For example, for BDE 47, when all
women were included in the analysis, the odds of having
a current thyroid problem was 1.5 compared to 2.1 for
just postmenopausal women. For BDE 99, this difference
was two-fold, with postmenopausal women in the high-
est exposure category having 3.6 times the odds of hav-
ing a current thyroid problem (95 % CI: 1.1–11.8),
compared to 1.5 times the odds observed for all women
(95 % CI: 0.97–2.3). The analysis for a current thyroid
problem post-menopause showed odds ratios that were
less than unity for the 3rd quartile.
The NHANES dataset did not contain enough men
with current thyroid disease for our models to converge
in a men-only analysis. In an analysis with all men and
women combined, we did not find significant associa-
tions between the exposure categories and current thy-
roid disease (Table 1). Similarly, we originally attempted
to explore thyroid cancer specifically, but this NHANES
cycle only had nine participants reporting thyroid cancers,
precluding us from performing regression analysis.
Discussion
Our study found a positive association between PBDEs
in serum and thyroid disease in U.S. women, a finding
that suggests that effects of PBDEs on thyroid hormones,
documented extensively in toxicological and epidemio-
logical studies, is leading to significant downstream im-
pacts. For example, increased PBDE levels in animals,
primarily in mice and rats studies, have been associated
with altered T4 and T3 levels [46–50] suggesting thyroid
dysregulation in vivo, with several proposed mechanisms
of action [51–54]. Associations between thyroid hormone
levels and PBDEs have also been observed for animals in
Table 1 Survey-weighted prevalence of ever having a thyroid problem and having a current thyroid problem, by males v. females
and premenopausal v. postmenopausal
Gender/Status Prevalence (proportion) Linearized SE Lower 95 % CI Upper 95 % CI
Ever had a thyroid problem
All men (n = 2414) 0.03 0.009 0.02 0.06
All women (n = 2613) 0.16 0.017 0.13 0.20
Premenopausal women (n = 1070) 0.12 0.025 0.07 0.18
Postmenopausal women (n = 1144) 0.24 0.026 0.19 0.30
Current thyroid problem
All men (n = 2410) 0.02 0.009 0.01 0.05
All women (n = 2594) 0.13 0.015 0.10 0.17
Premenopausal women (n = 1065) 0.10 0.022 0.06 0.16
Postmenopausal women (n = 1.131) 0.18 0.027 0.13 0.24
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humans, there are many studies that describe similar
findings of associations between PBDE concentrations in
serum and thyroid hormone concentrations [21, 25, 26,
29, 58–61].
One possible mechanism accounting for the PBDE-
induced reduction in serum T4 is displacement of T4 from
the serum binding protein transthyretin (TTR) or thyroxine
binding globulin (TBG) [54]—similar to what has been
previously observed for polychlorinated biphenyls (PCBs)
[62]. (Significantly, a study examining the effects of chem-
ical mixtures observed a potentially synergistic effect on
T4 levels with co-exposures to BDE 47 and PCBs [47]).
T3 and T4 travel in blood bound to plasma proteins; only
0.04 % of T4 and 0.4 % of T3 are unbound (or “free”), andTable 2 Fully-adjusted, survey-weighted associations between serum
Adjusted for: age, race/ethnicity, BMI, education, smoking, alcohol co
BDE47 n = 1075 BDE99 n = 1061 BDE
OR (95 % CI) OR (95 % CI) OR
Men and Women Combined
Q1 + Q2 (ref) 1 1 1
Q3 0.55 (0.20–1.49) 0.93 (0.38–2.27) 0.74
Q4 1.32 (0.90–1.96) 1.22 (0.80–1.84) 1.13
BDE47 n = 512 BDE99 n = 504 BDE
All Women
Q1 + Q2 (ref) 1 1 1
Q3 0.60 (0.19–1.85) 0.75 (0.27–2.08) 0.65
Q4 1.48** (1.05–2.09) 1.78** (1.16–2.75) 1.50
BDE47 n = 236 BDE99 n = 233 BDE
Postmenopausal Women
Q1 + Q2 (ref) 1 1 1
Q3 0.81 (0.24–2.71) 0.99 (0.34–2.93) 0.23
Q4 2.15* (0.86–5.37) 3.63** (1.12–11.8) 2.02
***p < 0.01,**p < 0.05, *p < 0.1consequently, available for entry and action in target tis-
sues [32]. The tetra-brominated congeners, BDE 47 in
particular, share a similar structure to T4, with both having
the diphenyl ether structure and four halogens (iodine for
T4; bromine for BDE47). A major difference is that T4
has a hydroxyl group on one of the rings, positioned be-
tween the two halogens. However, PBDEs are hydroxyl-
ated in vivo and, when this occurs in the meta position, it
yields 3-OH-BDE47, which also has the hydroxyl group
positioned between two halogens [53].
Along with epidemiological and toxicological evidence
showing perturbations in thyroid hormone concentrations,
we are now beginning to understand plausible mechanisms
by which this disruption is occurring; the similarity of struc-
tures of exogenous chemicals to endogenous hormonesPBDE concentrations and having a current thyroid problem.
nsumption, and current hormone use
100 n = 1089 BDE153 n = 1089 Sum BDEs n = 1061
(95 % CI) OR (95 % CI) OR (95 % CI)
1 1
(0.44–1.25) 0.92 (0.30–2.84) 0.57 (0.23–1.39)
(0.79–1.60) 1.14 (0.56–2.31) 1.09 (0.71–1.67)
100 n = 518 BDE153 n = 518 Sum BDEs n = 504
1 1
(0.27–1.54) 1.00 (0.27–3.78) 0.36** (0.15–0.89)
* (0.97–2.31) 1.44 (0.68–3.05) 1.61** (1.10–2.36)
100 n = 240 BDE153 n = 240 Sum BDEs n = 233
1 1
** (0.07–0.68) 0.50 (0.13–1.90) 0.54 (0.15–1.97)
* (0.93–4.36) 1.25 (0.49–3.21) 2.20* (0.92–5.26)
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causing inhibition or amplification. For thyroid hormones,
a study by Cao et al. [52] found that hydroxylated PBDEs
bind to transthyretin (TTR) and thyroxine-binding globu-
lin (TBG) at the same sites as the target hormone, T4.
Hamers et al. measured binding affinities for PBDEs and
metabolites to TTR and reported that the hydroxylated
metabolites bound 160–1600 times more avidly than the
parent compounds [63]. Further, a study by Butt and
Stapleton [51] found that hydroxylated PBDEs are potent
inhibitors of thyroid hormone sulfation. Also relevant to
our study that focused on menopausal status, hydroxylated
PBDEs have been shown to compete with estrogen en-
zymes. A crystallographic analysis examining the binding
affinity of 3-OH-BDE47 to a hormone enzyme, estrogen
sulfotransferase, demonstrated that the first phenolic group
positions the compound within the enzyme similarly to
how 17βestradiol would situate [41]. Further, the authors
demonstrated that this positioning creates additional
hydrogen bonding via the hydroxyl group, also similar to
17βestradiol, while accommodating the two halogens.
Perhaps the most striking and unique finding in this
study is that the odds of having a current thyroid prob-
lem associated with PBDEs are so much higher in post-
menopausal women. One hypothesis is that this is
related to the change in hormone concentrations in
postmenopausal women and the affinity of PBDEs to
binding sites for both estrogen and thyroid hormones.
Menopause is initiated when the ovaries discontinue
producing two hormones, estrogen and progesterone.
In at least two ways, the strong binding affinity of
OH-PBDEs with estrogen sulfotransferase can interfere
with the change in estrogen levels that occur during
menopause. First, with less estrogen in the system, there
may be increased metabolism of PBDEs by this estrogen
enzyme [41]. Second, the OH-PBDEs may be competing
for these binding sites that are critical for the removal of
circulating estrogen produced by other tissues, leading to
higher than expected levels of circulating estrogen. This
potential interference of the estrogen clearance pathway
in the liver via estrogen sulfotransferase, in and of itself,
would not explain the higher odds of thyroid problems.
However, estrogen (and androgen) can increase the levels
of serum thyroxine binding globulin (TBG), interfering
with one of the three primary proteins responsible for
thyroid hormone transport in serum. In addition to these
potential impacts on thyroid hormone via estrogen-
mediated pathways, PBDEs can also have a direct impact
on thyroid hormones through serum binding proteins
outside of the mechanism that involves estrogen; PBDEs
show a strong affinity for both TBG and another serum
binding protein, transthyretin, and therefore can have a
more direct impact on circulating thyroid hormone levels
[41, 52]. All of this suggests the disruption of thyroidsignaling by PBDEs that may be enhanced by the altered
estrogen levels during menopause.
Results from epidemiologic studies on the effects of
PBDEs on thyroid hormones are consistent with the toxi-
cological evidence, in that they suggest interference with
thyroid hormone regulation. However, in some epidemio-
logic studies, estimates of PBDE exposure are positively
associated with measures of thyroid function, and in
others the opposite pattern is observed. For example, in a
study of 297 infants, Herbstman et al. observed that cord
blood serum PBDE levels were associated with reduced
total and free T4 levels [27]. Conversely, Turyk et al.
(2008) conducted a study of 405 adult male sport fish
consumer and observed a positive trend between free T4
and PBDE serum levels [61]. A more recent study found a
positive association between PBDEs in serum of pregnant
women and serum total and free T4 and T3 [29].
There are seeming inconsistencies, then, in the epi-
demiological literature, with some studies showing posi-
tive associations with PBDEs and thyroid hormones and
others showing negative associations. We note that the
PBDE serum concentrations in many of these cohort
studies are in different ranges of the concentration
distribution found in the U.S. population, with some
representing the low-end of exposure and others on the
high-end (selected studies; Table 3) [21, 25, 26, 29,
58–60]. Moreover, it seems reasonable to consider the
possibility that adults and fetuses have many differences in
thyroid physiology that could account for at least some of
these differences. However, we hypothesize that a poten-
tial explanation of the differences in findings is due to: 1)
non-monotonic dose responses to PBDEs, and 2) where
on the dose–response range the studies were performed.
Within our study using NHANES data, which represents
the full range of population exposures in the U.S. and
therefore in theory encompasses the ranges found in these
other studies, we also observed that the shape of the
response curve is non-linear and suggests a non-monotonic
dose response curve (NMDRC) may exist (e.g. Q1 +Q2
have higher odds of current thyroid problem relative to
Q3; Q4 also has higher odds of current thyroid problem
relative to Q3). Vandenberg et al. [64] published a seminal
paper evaluating the literature related to endocrine dis-
rupting chemicals and low-dose and nonmonotonic dose
responses, with significant implications to our current ap-
proach to protecting public health [65]. Vandenberg et al.
state that NMDRCs are, “not the exception, but should be
expected and perhaps even common,” and that it is no
longer acceptable to dismiss NMDRCs based on a lack of
mechanism because there are now several potential mech-
anisms to explain these phenomena [64]. These include
cytotoxicity (toxic at high concentrations and biologically
active at low concentrations), cell- and tissue-specific re-
ceptors and co-factors, receptor sensitivity, and receptor
Table 3 Selected studies reporting associations between serum BDE 47 concentrations (ng/g lipid) and associations with thyroid
hormone, in relation to NHANES serum concentrations
NHANES
(all participants)
25th percentile 9.3 50th percentile 19.2 75th percentile
40.9
















n 110 623 36 270 405 140 380 25












1.04 2.16 7.9 15.3 16.2# 16.5 21.5 43.1
TSH -* - - -* - + + +
Total T3 +* -* + -*
Free T3 - + +
Total T4 - - +* -* +
Free T4 + + + + +* +* -
+ positive association
- Negative association
* p < 0.05
# estimated
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posed mechanisms. In our analysis, individuals in the first
and last quartiles (Q1 +Q2 and Q4) have higher odds of a
thyroid problem, compared to Q3. Results from the other
study of PBDEs using NHANES that focused on diabetes
and metabolic syndrome were also suggestive of a NMDRC
for BDE 99 [39]. It is possible that the existence of a
NMDRC for PBDEs may explain the seeming inconsistency
across studies examining the relationship between PBDEs
and thyroid hormones. The serum concentrations in these
studies generally fall within very different ranges of the full
distribution of serum concentrations observed in NHANES
(Table 3). For example, the central tendency PBDE concen-
trations in Zota et al. [21] fall within the Q4 of NHANES,
and they found that PBDEs were associated lower free T4.
In contrast, the central tendency PBDE concentrations in
Abdelouahab et al. [25] fall within Q3 of NHANES, and
they found that PBDEs were associated with the opposite
effect (higher free T4). More research is needed to fully
explore this hypothesis.
A limitation of our study is the inability of this analysis
to determine causality because the data are cross-
sectional; thus, we do not have temporality captured in
the data to know if the exposure preceded the outcome.
Also, the standard approach to analysis of serum concen-
trations for lipophilic compounds is to adjust the concen-
trations based on lipid-content in the serum and report
the results as ‘lipid-adjusted’. This approach, however,
may have a critical limitation. Thyroid hormones affect
lipid metabolism at several points—synthesis, mobilization
and degradation [66]. If a person has thyroid disease not
caused by PBDE exposure, and the disease increases lipid
metabolism leading to lower lipids in the bloodstream,then adjusting PBDEs by this lower lipid concentration
yields a higher lipid-adjusted PBDE concentration, creating
the appearance of a positive association between thyroid
disease and PBDEs. Therefore, it is possible that women
who self-report current thyroid disease have elevated lipid-
adjusted PBDE concentrations in serum as a result of hav-
ing thyroid disease. Further, even if serum concentrations
are not adjusted for lipid content, the concentration in
serum is still impacted by lipid content in the bloodstream,
so a simple solution cannot be using serum concentrations
that are not lipid-adjusted (we performed an analysis using
wet-weight concentrations and found similar results as
when we used lipid-normalized concentrations; Additional
file 1: Table S1). Considering these points, it is plausible
then that the relationship of thyroid dysfunction to PBDEs
could be a function of reverse causality, with PBDE con-
centrations, lipid-adjusted or not, simply an outcome of
thyroid dysfunction and altered lipid metabolism.
Another potential limitation of this study is the lack
of specificity in the NHANES questionnaire regarding
thyroid problems. NHANES is a nationally representative
health survey (U.S.) that, due to its breadth, only covers
thyroid-related disease with three non-specific questions:
1) Has your doctor ever told you that you have a thyroid
problem, 2) Do you still have a thyroid problem, and
3) Do you have thyroid cancer. Yet, ‘thyroid problem’
and ‘thyroid cancer’ encompass a wide range of specific
illnesses (e.g., hyperthyroidism, hypothyroidism, nodules,
thyroiditis, goiter; papillary thyroid cancer, follicular
thyroid cancer, medullary thyroid cancer), each with their
own potential etiology (e.g., iodine deficiency, Graves’
disease, Hashimoto’s disease, radiation, environmental
chemicals). Despite the lack of specificity in the NHANES
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bias the results toward a null finding, we still observed
strong and consistent associations between PBDEs in
serum and thyroid problems. Last, the congeners available
for analysis in NHANES are also from the same commer-
cial product and are correlated in environmental and body
burden samples [5, 42]. Therefore, we cannot rule out that
one congener is driving the observed associations seen for
several congeners.
Overall, the findings from this analysis of data reported
in NHANES provide additional evidence of the impact
of PBDEs on the thyroid. We also observed a stronger
effect for postmenopausal women. Additional research
is warranted to confirm these findings, particularly
when the next cycle of NHANES data with PBDE serum
concentrations is made available.Conclusion
We found that women with the highest flame retardant
concentrations in their blood were significantly more
likely to have a thyroid problem, with stronger associa-
tions found for post-menopausal women. Specifically,
women with lipid-adjusted serum concentrations of BDE
47, 99 and 100 in the highest quartile of exposure had
higher odds of having a current thyroid problem com-
pared to women with lower serum concentrations. These
associations were much stronger in an analysis that was
restricted to postmenopausal women.Ethics
This research did not require ethics approval by an Insti-
tutional Review Board (IRB) as the data are de-identified
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